A2T Stock Overview
A biomedical company, provides diagnostic services and medical treatments. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Atrys Health, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €3.04 |
| 52 Week High | €4.14 |
| 52 Week Low | €2.45 |
| Beta | 0.56 |
| 11 Month Change | -5.00% |
| 3 Month Change | -8.71% |
| 1 Year Change | -16.02% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -67.03% |
Recent News & Updates
Recent updates
Shareholder Returns
| A2T | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | 4.1% | 0.1% | -1.5% |
| 1Y | -16.0% | 18.0% | 7.9% |
Return vs Industry: A2T underperformed the German Healthcare industry which returned 18% over the past year.
Return vs Market: A2T underperformed the German Market which returned 7.9% over the past year.
Price Volatility
| A2T volatility | |
|---|---|
| A2T Average Weekly Movement | 5.5% |
| Healthcare Industry Average Movement | 3.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: A2T has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: A2T's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 2,084 | Isabel Lozano Fernandez | www.atryshealth.com |
Atrys Health, S.A., a biomedical company, provides diagnostic services and medical treatments. The company offers diagnostic services in the fields of pathology, hematology, molecular pathology, and genetics; and diagnostic second opinion, test directory, and clinical trials and R&D services. It uses telemedicine to provide its services in the medical specialties of radiology, cardiology, ophthalmology, and dermatology.
Atrys Health, S.A. Fundamentals Summary
| A2T fundamental statistics | |
|---|---|
| Market cap | €246.80m |
| Earnings (TTM) | -€31.51m |
| Revenue (TTM) | €211.11m |
1.2x
P/S Ratio-7.8x
P/E RatioIs A2T overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A2T income statement (TTM) | |
|---|---|
| Revenue | €211.11m |
| Cost of Revenue | €155.67m |
| Gross Profit | €55.44m |
| Other Expenses | €86.95m |
| Earnings | -€31.51m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.41 |
| Gross Margin | 26.26% |
| Net Profit Margin | -14.93% |
| Debt/Equity Ratio | 80.9% |
How did A2T perform over the long term?
See historical performance and comparison